These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Migliorati CA, Siegel MA, Elting LS. Lancet Oncol; 2006 Jun; 7(6):508-14. PubMed ID: 16750501 [Abstract] [Full Text] [Related]
5. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM. Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259 [Abstract] [Full Text] [Related]
6. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, Delaroudis S. Am J Otolaryngol; 2007 Aug; 28(3):158-63. PubMed ID: 17499130 [Abstract] [Full Text] [Related]
12. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R, Baumann A. Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978 [Abstract] [Full Text] [Related]
13. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy. Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R, Lo Muzio L. J Clin Oncol; 2006 Mar 20; 24(9):1475-7. PubMed ID: 16549843 [No Abstract] [Full Text] [Related]
14. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. J Clin Oncol; 2005 Dec 01; 23(34):8580-7. PubMed ID: 16314620 [Abstract] [Full Text] [Related]
15. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Cancer; 2005 Jul 01; 104(1):83-93. PubMed ID: 15929121 [Abstract] [Full Text] [Related]
16. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma. Diego R, D'Orto O, Pagani D, Agazzi A, Marzano U, Derada Troletti G, Fontanella W, Pignataro L. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar 01; 103(3):e1-5. PubMed ID: 17197204 [Abstract] [Full Text] [Related]
17. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid. García Sáenz JA, López Tarruella S, García Paredes B, Rodríguez Lajusticia L, Villalobos L, Díaz Rubio E. Med Oral Patol Oral Cir Bucal; 2007 Sep 01; 12(5):E351-6. PubMed ID: 17767097 [Abstract] [Full Text] [Related]
18. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Olson KB, Hellie CM, Pienta KJ. Urology; 2005 Sep 01; 66(3):658. PubMed ID: 16140106 [Abstract] [Full Text] [Related]
20. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. Clin Ther; 2007 Aug 01; 29(8):1548-58. PubMed ID: 17919538 [Abstract] [Full Text] [Related] Page: [Next] [New Search]